FPAS
IKT icon

Focus Partners Advisor Solutions’s Inhibikase Therapeutics IKT Stock Holding History

Focus Partners Advisor Solutions’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,886
Closed -$20K – 1331
2026
Q1 		$20K Buy
11,886
+1,167
+11% +$2.07K ﹤0.01% 1242
2025
Q4 		$22K Buy
10,719
+11
+0.1% +$18 ﹤0.01% 1081
2025
Q3 		$17.3K Hold
10,708
– – ﹤0.01% 1130
2025
Q2 		$20.9K Buy
+10,708
New +$21K ﹤0.01% 1090

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Focus Partners Advisor Solutions's IKT Position: Q2 2026 in Review

Focus Partners Advisor Solutions sold out of Inhibikase Therapeutics (IKT) in Q2 2026, closing a stake of 11,886 shares — an estimated $20K sold.

Focus Partners Advisor Solutions first reported a position in IKT in Q2 2025 and held it in 4 quarters. The position peaked at $22K in Q4 2025. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Focus Partners Advisor Solutions reported no remaining Inhibikase Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Focus Partners Advisor Solutions sold 11,886 Inhibikase Therapeutics shares in Q2 2026, an estimated $20K.
  • Focus Partners Advisor Solutions first reported a position in Inhibikase Therapeutics in Q2 2025 and held it in 4 quarters.
  • Focus Partners Advisor Solutions's Inhibikase Therapeutics position peaked at $22K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.